Status: Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Participants needed: 404
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: BriaCell Therapeutics CorporationUpdated: Apr 7, 2026Locations: 79
Eligibility criteria
Be ≥ 18 years of age. [+14]
Concurrent or recent chemotherapy, immunotherapy or major surgery within 21 days... [+28]